Research output per year
Research output per year
Research Resources Details
Description
The Histopathology Facility (HF) provides Cancer Center members with technical processing of cells and tissues, gene expression in situ protein immunolocalization, pathology interpretation of microscopy findings, including target distribution and other metrics focused on particular cell/tissue compartments. We help establish and characterize animal models of human cancer and related diseases, as well as analysis of human tissue samples, including from clinical trials. Most projects involve animal models that require complex histological, immunohistochemical and/or cytological processing to determine morphological alterations, and to localize and quantify the expression of cancer-relevant gene products in tissue sections, including murine and human samples.
This facility derives partial funding from the FCCC Cancer Center Support Grant (CCSG) from the National Cancer Institute.
This facility derives partial funding from the FCCC Cancer Center Support Grant (CCSG) from the National Cancer Institute.
×
![]()
Fingerprint
Explore the research areas in which this equipment has been used. These labels are generated based on the related outputs. Together they form a unique fingerprint.
-
ALDH2 dysfunction and alcohol cooperate in cancer stem cell enrichment
Flashner, S., Shimonosono, M., Tomita, Y., Matsuura, N., Ohashi, S., Muto, M., Klein-Szanto, A. J. P., Diehl, J. A., Chen, C.-H., Mochly-Rosen, D., Weinberg, K. I. & Nakagawa, H., Jan 1 2024, In: Carcinogenesis. 45, 1-2, p. 95-106 12 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
Australian Ovarian Cancer Study, Aug 5 2024, In: MOLECULAR CANCER. 23, 1, p. 158 1 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS): Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Movva, S., Matloob, S., Handorf, E. A., Choy, E., Merriam, P., Flieder, D. B., Cai, K. Q., Zhou, Y., Tetzlaff, E. D., Pagan, C., Barker, E., Veggeberg, R., Zumpano, D., Rink, L., von Mehren, M. & George, S., Jan 15 2024, In: Clinical Cancer Research. 30, 2, p. 315-322 8 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations